Utilisation and predictors of genomic testing prior to firstline (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)

by on 15 de novembre de 2021 with No hi ha comentaris
  • Lenz, H. J., Weberpals, J., Cremolini, C., Grothey, A., Leutgeb, B., Mahrus, S., . . .Tabernero, J., … Stintzing, S. (2021). Utilisation and predictors of genomic testing prior to firstline (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology, 32, S569-S570. https://doi.org/10.1016/j.annonc.2021.08.998 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *